AMP studies demonstrate proof of concept of passive immunization for HIV prevention

The IAS-led Global HIV Vaccine Enterprise welcomes new results from the AMP proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections.

VIDEO recording available – Making mAb Accessible webinar

VIDEO – Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’

The video recording of the Global HIV Vaccine Enterprise and IAVI webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention is now available online.

HVTN 084 – Injectable HIV drug prevents infections

The IAS hosted Global HIV Vaccine Enterprise welcomes interim results showing effectiveness of long-acting injectable PrEP. New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill in a trial of women at increased risk of HIV acquisition.